Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinosarcoma × Trabectedin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 19 Ovarian Neoplasms 7 Leiomyosarcoma 5 Liposarcoma 4 Liposarcoma, Myxoid 3 Sarcoma, Ewing 2 Osteosarcoma 2 Solitary Fibrous Tumors 1 Sarcoma, Synovial 1 Rhabdomyosarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Epithelial Cancer Recurrent 1 Mesothelioma, Malignant 1 Mesothelioma 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leiomyosarcoma Uterus 1 Ichthyosis, X-Linked 1 Histiocytoma, Malignant Fibrous 1 Hemangioendothelioma 1 Fanconi Anemia, Complementation Group D1 1 Chondrosarcoma 1 Carcinosarcoma 1 Cancers With DNA Repair-Deficiency 1 Bone Neoplasms 1

Interventions

Specimen Handling 3 Paclitaxel 3 Nivolumab 3 olaparib 2 X-Rays 2 Carboplatin 2 Biopsy 2 sargramostim 1 pembrolizumab 1 pazopanib 1 pamiparib 1 durvalumab 1 ceralasertib 1 cediranib 1 atezolizumab 1 apatinib 1 Trabectedin 1 Tissue Banks 1 TIC10 compound 1 Minimally Invasive Surgical Procedures 1 Magnetic Resonance Spectroscopy 1 LY-2157299 1 Indocyanine Green 1 Immunoglobulin G 1 Gemcitabine 1 Cyclophosphamide 1 Colony-Stimulating Factors 1 Cisplatin 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02993705 2021-08-25

MITO 26

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Completed

Carcinosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡